Elevate your enterprise data technology and strategy at Transform 2021.
San Francisco drug developer Prosetta
announced that it brought in $5 million in second-round funding to begin clinical trials on its lead compounds. All of the contributors were individuals, reports VentureWire.
So far, the company has resisted raising venture capital, relying solely on angel investors to cushion itself from the economic downturn. Most of its projects remain secretive, but it says its currently working on small molecules that could disrupt the synthesis of the protein coats that protect viruses.
Previously, Prosetta raised $8 million in first-round funding. It says that most of its research and development financing comes from government grants and contracts.
VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact.
Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
Become a member
- up-to-date information on the subjects of interest to you
- our newsletters
- gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
- networking features, and more